OSI Pharmaceuticals Inc. (OSIP)

All Comments on OSIP

  • commenter
    Olboy2
    Aug 13 02:56 PM
    Cancer Stocks on the Go: Winners and Losers [view article]
    I agree with paviov, However I would like to know about the new developments the phase II and III studies that are going well, where is the advancement taking place, how close to a cure, what company has the potential winning drug ?? Reply
  • commenter
    Norman
    Lepoff, M.D.
    Aug 06 10:15 PM
    Oncology Conference Countdown: What Will Pharma and Biotech Companies Report? [view article]
    Dear Mr. Mizerak,

    I am a reitired Ophthalmologist. I am not sure I haev the expertise you need.     Reply
  • commenter
    optiondragon
    Jul 29 02:44 PM
    My Website
    A Biotech Bloom in July [view article]
    Murph, thanks man! I like IBB and XBI. I like your website. Reply
  • commenter
    optiondragon
    Jul 28 09:00 PM
    My Website
    A Biotech Bloom in July [view article]
    runtolive, in DNA's recent CC they were still excited about DM-1 which uses Immunogen's drug delivery technology. Reply
  • commenter
    optiondragon
    Jul 28 08:57 PM
    My Website
    A Biotech Bloom in July [view article]
    runtolive, yes they are scheduled to come out with data in the fourth quarter and it will move the stock of IMGN, I will be on its trail. Reply
  • commenter
    beta delta
    Jul 28 08:32 PM
    A Biotech Bloom in July [view article]
    option dragon.. you should look into immunogen .. imgn and dna have a drug in multiple phase 2 trials and soon a phase 3 trial, trastuzumab-dm1 for metastatic breast cancer. it kills all previous data for herceptin in trials, and may be one of the drivers for Roche wanting a deal for genentech.Herceptin has sales of 4.5 billion worldwide and its very likely that trastuzumab-dm1 may encroach on those sales as genentech much pay a royalty to immunogen on the sales of the new drug. Reply
  • commenter
    b0572
    Jul 28 03:20 PM
    A Biotech Bloom in July [view article]
    This is a hoax website which the yahoo board believes is an attempt by Purdue Pharma to discredit Acura.

    See the following link on the Yahoo Message Board.

    messages.finance.yahoo...     Reply
  • commenter
    optiondragon
    Jul 28 02:15 PM
    My Website
    A Biotech Bloom in July [view article]
    ACUR no I haven't but looking at the technicals it looks weak right now so its best to let it vent and wait for some strength and pinpointing the catalyst time frame before trading it or investing in it. IMO
    Here is a good article from another SA writer about it....seekingalpha.com/artic...     Reply
  • commenter
    b0572
    Jul 28 11:41 AM
    A Biotech Bloom in July [view article]
    Optiondragon, have you looked at the abuse deterrent technologies? Acura (ACUR) Pharmaceuticals has just completed a P3 on Acurox. NDA is expected before year end. They have many more in the pipeline and expect fast track FDA approval. Reply
  • commenter
    optiondragon
    Jul 28 10:30 AM
    My Website
    A Biotech Bloom in July [view article]
    WACG- forggot about them....will add to my list and do analysis on release date for data but yes that should be a big mover too....thank you for the reminder. Reply
  • commenter
    WACG
    Jul 28 09:42 AM
    A Biotech Bloom in July [view article]
    Obviously you have not been doing your homework. One of the biggest price catalysts coming down the pike are the Byetta LAR announcements from AMLN. Reply
  • commenter
    jturano7423
    Jul 28 07:17 AM
    A Biotech Bloom in July [view article]
    FANTASTIC ARTICLE! Good job. Of course not all bloomed nicely. There are always some weeds and the SEC should be the ones who pull them out.
    Example, 'MRNA'. There has been so much damage to investors to date, that management ought not to be able to continue to pay themselves & exist for another 5,10, or 20 years. A total injustice to all!     Reply
  • commenter
    User 227706
    Jul 17 01:19 PM
    Oncology Conference Countdown: What Will Pharma and Biotech Companies Report? [view article]
    Dear Dr. Norman Lepoff,

    I am a retired Principal Biochemist and recognized expert in carbohydrate chemistry with 5 US Patents. I have worked out a novel anti-cancer therapy that I would like to discuss with you in private rather than in a public forum. Can you send me your private contact information for a confidential yet thorough discussion? I think that you will be impressed. I ultimately hope to obtain from you the names of contact individuals in oncological research, preferably at the big pharmaceutical houses.

    Thank you,
    Robert J. Mizerak
    (Oconomowoc, WI)
    Reply
  • commenter
    Brewer
    May 30 01:01 PM
    Will Yahoo Settle? Fast Money Recap (5/28/08) [view article]
    I hope MSFT does go in debt to buy Yahoo. As if MS didn't already have their own failed search division, and failed internet division.

    Expect a sucker punch from Apple about that time. Apple has in it's skunkworks, a dumbed down version of OS X that runs on any generic PC. It has far more going for it than any version of windows, still leaves a reason to buy a real macintosh, but could totally destroy MS's marketshare within months. Microsoft still has the toy business to fall back on with the Xbox line.     Reply
  • commenter
    David White
    May 29 02:25 PM
    Will Yahoo Settle? Fast Money Recap (5/28/08) [view article]
    Apparently a finance firm Kaufman Bros., with no previous experience in the solar arena, published ratings on 6 stocks in this arena. Notably they gave SPWR (P/E approx. 300 on Yahoo) a buy and SFLR a hold (P/E approx. 100 on Yahoo). Seems questionable to me since FSLR has historically outstripped SPWR in growth and consistently good earnings reports. FSLR may be getting more competition, but so is everyone else. If SPWR is a buy, I would think you would have to consider FSLR a buy also. Yahoo states its actual analyst average rating is 2.2 (a buy). Reply

Trading Center


Loading...
Symbols:
Authors:
Quick Links: